Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 1 art units • 2 examiners • 0 of 3 (0%) have an AI response strategy ready
Invetx Inc. is currently managing 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are being reviewed by 2 distinct examiners, yet they are all concentrated within 1 distinct art unit. This concentration in a single art unit suggests a very specific technical focus for the company's current patent applications. The busiest examiner, DAHLE, CHUN WU, is handling 2 pending office actions.
With 3 pending office actions and only 2 distinct examiners, there is a significant overlap in the personnel reviewing the company's filings. DAHLE, CHUN WU is responsible for the majority of the workload with 2 pending office actions. The fact that all matters reside in 1 distinct art unit may allow for more consistent examiner feedback across the portfolio. This structure provides a streamlined view of the company's biotechnology prosecution efforts. The 3 pending office actions represent the entirety of the current active examination for the firm.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DAHLE, CHUN WU | 2 | 50.2% | +51.2% |
| BENAVIDES, JENNIFER ANN | 1 | 51.2% | +47.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18427351 | COMPOSITIONS FOR INCREASING HALF-LIFE OF A THERAPEUTIC AGENT IN CANINES AND METHODS OF USE | DAHLE, CHUN WU | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18061755 | COMPOSITIONS FOR INCREASING HALF-LIFE OF A THERAPEUTIC AGENT IN CANINES AND METHODS OF USE | DAHLE, CHUN WU | 7d |
| 18427351 | COMPOSITIONS FOR INCREASING HALF-LIFE OF A THERAPEUTIC AGENT IN CANINES AND METHODS OF USE | DAHLE, CHUN WU | — |
| 18396160 | POLYPEPTIDES WITH ALTERED BINDING TO NEONATAL FC RECEPTOR (FCRN) AND METHODS OF USE | BENAVIDES, JENNIFER ANN | — |
| Art Unit | Apps |
|---|---|
| 1641 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18427351 | COMPOSITIONS FOR INCREASING HALF-LIFE OF A THERAPEUTIC AGENT IN CANINES AND METHODS OF USE | DAHLE, CHUN WU | — | §102§112 | Non-Final OA | — | Pending | Jan 30, 2024 |
| 18396160 | POLYPEPTIDES WITH ALTERED BINDING TO NEONATAL FC RECEPTOR (FCRN) AND METHODS OF USE | BENAVIDES, JENNIFER ANN | — | §103DP | Non-Final OA | — | Pending | Dec 26, 2023 |
| 18061755 | COMPOSITIONS FOR INCREASING HALF-LIFE OF A THERAPEUTIC AGENT IN CANINES AND METHODS OF USE | DAHLE, CHUN WU | 1641 | §103 | Final Rejection | 7d | Pending | Dec 05, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial